Search Results

BS-181 hydrochloride 50 mg  | 99.97%

TargetMol

BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

More Information Supplier Page

BS-181 hydrochloride 25 mg  | 99.97%

TargetMol

BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

More Information Supplier Page

GSK-J4 2 mg  | 97.07%

TargetMol

GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]

More Information Supplier Page

GSK-J4 25 mg  | 97.07%

TargetMol

GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]

More Information Supplier Page

GSK-J4 10 mg  | 97.07%

TargetMol

GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]

More Information Supplier Page

Galunisertib 50 mg  | 97.09%

TargetMol

Galunisertib is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.

More Information Supplier Page